Add Altimmune (ALT +81.8%) to the list of coronavirus plays, after it reported completion of first development milestone toward a single-dose intranasal coronavirus vaccine.
Altimmune says it has completed the design and
synthesis of the vaccine and is now advancing it toward animal testing
and manufacturing.
The new intranasal vaccine is based on the same
platform vaccine technology as NasoVAX, the company’s influenza vaccine
candidate.
https://seekingalpha.com/news/3547123-altimmune-nearly-doubles-after-advancing-intranasal-coronavirus-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.